Absci (ABSI) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Absci (ABSI) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 146.5% versus a loss of 24.3%. Over five years, ABSI leads with a -13.3% price change compared with -79.2% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.85 billion vs $1.58 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | SRPT |
|---|---|---|
| Share price | $9.22 | $17.50 |
| Market cap | $1.58B | $1.85B |
| 1-day change | -10.22% | +1.10% |
| YTD return | +164.18% | -18.68% |
| 1-year return | +146.52% | -24.31% |
| 5-year return | -13.26% | -79.21% |
| Forward P/E | — | 7.26 |
| EPS (TTM) | $-0.79 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $24.68 |
| 52-week low | $2.24 | $14.68 |
| Distance from 52-week high | -23.52% | -29.09% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +56.18% | +24.17% |
| Average volume | 3.42M | 2.99M |
| Shares outstanding | 171.61M | 105.63M |
| Employees | 140 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed SRPT by 170.8 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
ABSI vs SRPT FAQ
Which is bigger, Absci or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.85B compared with $1.58B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or SRPT?
ABSI returned +146.52% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Sarepta Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Pharmaceutical Preparations for Sarepta Therapeutics.